1 / 40

ADVANCE ANGIOPLASTY 2004 LONDON, Jan 15-16 2004 LATEST CLINICAL EVIDENCE WITH DEXAMET GERMANO DI SCIASCIO, MD, FACC, FE

ADVANCE ANGIOPLASTY 2004 LONDON, Jan 15-16 2004 LATEST CLINICAL EVIDENCE WITH DEXAMET GERMANO DI SCIASCIO, MD, FACC, FESC Professor and Chairman of Cardiology, Campus Bio-Medico University of Rome. Dexamet TM is the Bio divYsio PC coated stents preloaded with Dexamethasone.

dahlia
Télécharger la présentation

ADVANCE ANGIOPLASTY 2004 LONDON, Jan 15-16 2004 LATEST CLINICAL EVIDENCE WITH DEXAMET GERMANO DI SCIASCIO, MD, FACC, FE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ADVANCE ANGIOPLASTY 2004 LONDON, Jan 15-16 2004 LATEST CLINICAL EVIDENCE WITH DEXAMET GERMANO DI SCIASCIO, MD, FACC, FESC Professor and Chairman of Cardiology, Campus Bio-Medico University of Rome

  2. DexametTM is the BiodivYsio PC coated stents preloaded with Dexamethasone • BiodivYsio Interdependent cell design • Non-inflammatory PC coating • Non-thrombogenic PC coating • Long term implant history Arterial Side 0.5 µg/mm2 Dexamethasone PC coating 1 mm } Targeted drug delivery direct to arterial wall Stent Strut Stent strut cross-section Lumen Side

  3. Dexamethasone • is a potent anti-inflammatory agent that treats the first step of the neointima formation/restenosis process • has also anti-proliferative action by affecting the inflammation process • is non-cytotoxic and does not destroy healthy cells and does not reduce or slow down the re-endothelisation 1 S.H.Park and A.M.Lincoff, Semin. Interv. Cardiol., 1998, 3, 191-195

  4. Dexamethasone (II) • is delivered (when it’s most needed) early to target the inflammatory cells • has strong clinical experience in humans •  demonstrated clinical benefits preferably in unstable in STRIDE and SAFE 1 S.H.Park and A.M.Lincoff, Semin. Interv. Cardiol., 1998, 3, 191-195

  5. Dexamet’s first clinical trial :STRIDE Study of anti-restenosis with BiodivYsio Dexamethasone-Eluting stent - A pilot Phase II trial, multi-centre, prospective, non-randomised study. Dexamethasone dose 0.5 ug/mm2 - 71 patients in 8 centres in Belgium - PI: Ivan De Scheerder - Endpoints: - 30-day and 6-month MACE - In-stent restenosis 6 months - Clinical and QCA :Late loss, loss index,MLD

  6. STRIDE STudy of Anti-Restenosis with BIodivYsioDexamethasone-Eluting Stent 71 patients with 6-month angiographic follow-up Stent: BiodivYsio stent (dexamethasone 45 μg) Unstable angina Stable angina p=0.017 % in-stentstenosis MACE at 30 days = 1% (TLR =1%) MACE at 6 months = 3% (TLR=3%) MACE at 12 months: 3% (TLR=3%)

  7. PC coated stents without Dexamethasone BiodivYsio TrialsLate Loss Comparisons

  8. First registry of DexametTM : SAFE - A multi-centre registrywith DexametTM & Dexamet SV - PI: Dr Pieter Stella, Utrecht, Netherlands - 1000“Real-world” patients with no specific inclusion/exclusion criteria - patients must meet the indications specified in the Directions For Use - 66 centres over 16 countries in Europe, Middle-East, Africa and Asia-Pacific - Endpoints are in-hospital, 30-day and 6-month MACE - Results available at JIM 2004

  9. DEXAMETHASONE-ELUTING STENTS IMPROVE SIGNS OF INFLAMMATION IN PATIENTS WITH UNSTABLE CORONARY SYNDROMES UNDERGOING PERCUTANEOUS CORONARY INTERVENTION G. Patti, A. D’Ambrosio, A. Carcagni’, M. Cortes-Morichetti, P. Carminati, G. Di Sciascio CAMPUS BIOMEDICO UNIVERSITY OF ROME

  10. DEXAMETHASONE-ELUTING STENTS IN UNSTABLE CORONARY SYNDROMES Methods Study design: case-control study with prospective evaluation Population: 60 pts receiving dexamethasone-eluting stent (Dexamet, N=30) or Biodivysio phosphorylcholine-coated stent (N=30) Inclusion criteria: - unstable angina (IIB-IIIB) or angina post recent (< 1 mo) myocardial infarction - angiographic evidence of “complex” coronary lesions that could be covered by a single stent Plasma levels of CRP were measured at: - 3 to 6 hours before PCI - 6, 24, 48 hours and 7 days after PCI Follow-up assessment: occurrence of MACE (myocardial infarction, death, repeat revascularization)

  11. DEXAMETHASONE-ELUTING STENTS IN UNSTABLE CORONARY SYNDROMES 18 15 * P=0.041 vs non DES ** P=0.026 vs non DES 11.4 12 9.8 9 CRP mg/l 5.2 DexametTM 6 3.6 2.8 5.8 5.4 * 3.7** 3 3.2 Non DES 2.3 0 Pre 6 h post 24 h post 48 h post 7 days post

  12. DEXAMETHASONE-ELUTING STENTS IN UNSTABLE CORONARY SYNDROMES 400 396 326 350 300 P=0.03 250 P=0.01 CRP % increase from baseline Non DES 200 152 DexametTM 150 85 93 100 32 50 0 24 h 48 h 7 days

  13. DEXAMETHASONE-ELUTING STENTS IN UNSTABLE CORONARY SYNDROMES 199 P=0.009 200 Baseline CRP <3 mg/l (N=19) 160 121 CRP percent increase from baseline 96 120 69 80 40 Baseline CRP3 mg/l (N=11) 14 40 0 24 h 48 h 7 days

  14. DEXAMETHASONE-ELUTING STENTS IN UNSTABLE CORONARY SYNDROMES Event-free survival curves 100 80 P=0.06 60 % of patients Dexamet 40 Non DES 20 0 0 1 2 3 4 6 months after stenting

  15. CONCLUSIONS • Dexamethasone-eluting stents improve early inflammatory response after PCI; this effect is more evident in pts with higher baseline CRP status • The sustained attenuation of CRP values at 7 days may suggest early plaque stabilization with dexamethasone-eluting stents in pts with unstable coronary syndromes • Clinical follow-up at 6 months shows a trend towards favorable intermediate-term results • Will steroid-eluting stents be the treatment of choice for pts with unstable coronary syndromes?

  16. RESULTS Patti, Di Sciascio et al. – Am J Cardiol P = 0.09 27 30 25 20 16% MACE during the follow-up (%) 15 10 5 5 0 1 2 3 4 Pre-procedural CRP Quartiles

  17. From morphology ................ To plaque “biology”

  18. Distribution of CRP plasma levels P=0.046 P=0.07 ³1,20 P=0.66 0,80 CRP (mg/dl) 0,40 0 Controls N=12 Stable angina N=49 Unstable angina N=57 Patti, Di Sciascio et al. – IL-1Ra: a sensitive marker of instability in patients with coronary artery disease J Thromb Thrombol 2002; 14: 139

  19. Patti, Di Sciascio et al. Prognostic value of IL-1Ra in patients undergoing percutaneous coronary intervention– Am J Cardiol 2002; 89: 372 P = 0.008 33 MACE during the follow-up (%) 0 1 2 3 4 Pre-procedural IL-1Ra Quartiles

  20. Arterial Injury Dexamethasone reduces Inflammation: PC reduces thrombus formation Arterial injury - Neutrophils - Monocytes - Macrophage - Lymphocytes Growth Factors & cytokines Thrombus Inflammation Growth Factors & cytokines Reduced Receptor activation Smooth muscle cell (SMC) Smooth muscle cell SMC receptors Signal transduction S Signal transduction Cell cycle G0 G1 G2 cell cycle M SMC Proliferation Reduces SMC Proliferation Matrix secretion Migration Migration Matrix secretion Dual mechanism of action of: PC coating and Dexamethasone

  21. THERMOGRAPHY in ACUTE CORONARY SYNDROMES • Temperature of the plaque is inversely correlated to cap thickness (Casscells W, Lancet 1996) • Pts presenting with AMI and unstable angina have significantly more temperature heterogeneity in their coronary atherosclerotic plaques than pts with stable angina (Stefanadis C, Circulation 1999). • Temperature was found to be the most powerful predictor of outcome (Stefanadis C, Circulation 2000) and to have a significant correlation with CRP levels (Stefanadis C, J Mol Cell Cardiol 2000)

  22. Inflamed plaque

  23. 300 pts, 824 specimens Di Sciascio et al. – Am Heart J 1994; 128: 419-26 Di Sciascio, Patti – Cardiologia 1999; 44: 333-9

  24. 0.002°C sensitivity

  25. Liuzzo, Maseri et al. The prognostic value of CRP and serum amyloid A protein in severe unstable angina. N Engl J Med 1994; 331: 417 % UA and CRP <0.3 mg/dl UA and CRP >0.3 mg/dl In-hosp. MACE Recurrent ischemia

  26. IL-1Ra in ischemic syndromes P=0.038 ³500 P=0.99 400 P=0.002 300 IL1-Ra (pg/ml) 200 100 0 Controls N=12 Stable angina N=49 Unstable angina N=47 Patti, Di Sciascio et al. – IL-1Ra: a sensitive marker of instability in patients with coronary artery disease J Thromb Thrombol 2002; 14: 139

  27. MACE-free survival % 100 IL-1Ra (1st quart.) 80 IL-1Ra (4th quart.) 60 40 20 0 months 0 3 6 12 18 Patti, Di Sciascio et al. Prognostic value of IL-1Ra in patients undergoing percutaneous coronary intervention– Am J Cardiol 2002; 89: 372

  28. Drug Eluting Stent Trials Late Loss (mm) (stable AP) (unstable AP) (Non-drug)

  29. Pepine CJ et al. A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group – Circulation 1990; 81: 1753 • 915 patients undergoing PTCA randomized to placebo or • 1 g methylprednisolone before the procedure • PTCA success rate 87% % Restenosis Placebo Steroids

  30. Oral prednisone therapy for 45 days in pts with elevated (>0.5 mg/dl) CRP levels 72 hours post PCI Versaci et al. Immunosuppressive therapy for the prevention of restenosis after coronary Artery stent implantation (IMPRESS study) – JACC 2002; 40: 1935

More Related